文献速递痛风与晶体性关节病

痛风患者使用钠-葡萄糖协同转运蛋白2抑制剂与磺脲类药物后的血清尿酸变化:一项比较有效性分析

Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysis.
PubMed 文献 · Semin Arthritis Rheum · 2024-04-05

本队列研究纳入基线血清尿酸>6 mg/dL且在SGLT2i或磺脲类药物启用前后90天内检测过血清尿酸的痛风患者,比较两组血清尿酸变化。SGLT2i组平均血清尿酸变化为-1.8 mg/dL,磺脲类组为+0.3 mg/dL,校正后两组差值为-1.8 mg/dL;无糖尿病者较有糖尿病者下降幅度更大。

要点

  • 痛风患者启用SGLT2i后平均血清尿酸变化为-1.8 mg/dL(95%CI -2.4至-1.1)。
  • 磺脲类组血清尿酸无变化(+0.3 mg/dL,95%CI -0.3至1.0)。
  • SGLT2i与磺脲类校正后血清尿酸变化差值为-1.8 mg/dL(95%CI -2.7至-0.9)。

核心结论

  • 在痛风患者中,与磺脲类相比,SGLT2i与血清尿酸显著降低相关,无糖尿病者降低幅度更大。
  • 作者认为,鉴于SGLT2i已证实的心血管-肾脏-代谢获益,将其加入现有痛风管理可为痛风及其合并症提供 streamlined 获益。

研究设计与样本

  • 队列研究,纳入基线血清尿酸>6 mg/dL且在SGLT2i或磺脲类药物启用前后90天内检测过血清尿酸的痛风患者。
  • 共识别28例启用SGLT2i的痛风患者(其中16例合并糖尿病)和28例启用磺脲类的患者(均合并糖尿病)。
  • 采用多变量线性回归比较SGLT2i启用者中有无糖尿病者的血清尿酸变化,并比较SGLT2i与磺脲类之间的血清尿酸变化。

主要发现

  • SGLT2i启用者组内平均血清尿酸变化为-1.8 mg/dL(95%CI -2.4至-1.1)。
  • SGLT2i启用者中,合并糖尿病者血清尿酸变化为-1.2 mg/dL(95%CI -1.8至-0.6),无糖尿病者为-2.5 mg/dL(95%CI -3.6至-1.3)。
  • 有无糖尿病者之间校正后差值为-1.4 mg/dL(95%CI -2.4至-0.5)。
  • 启用磺脲类后血清尿酸无变化(+0.3 mg/dL,95%CI -0.3至1.0)。
  • 所有患者中,SGLT2i与磺脲类启用之间校正后血清尿酸变化差值为-1.8 mg/dL(95%CI -2.7至-0.9)。

关键数值与推荐

  • 无论是否使用降尿酸治疗或利尿剂,以及是否存在糖尿病、慢性肾脏病或心力衰竭,SGLT2i的血清尿酸降低作用持续存在。

临床怎么用

  • 作者认为,鉴于SGLT2i已证实的心血管-肾脏-代谢获益,将其加入现有痛风管理可为痛风及其合并症提供 streamlined 获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the serum urate (SU) change among gout patients initiating SGLT2i, and to compare with sulfonylurea, the second-most widely used glucose-lowering medication after metformin. METHODS: We conducted a cohort study of patients with gout and baseline SU >6 mg/dL who had SU measured within 90 days before and after SGLT2i or sulfonylurea initiation. Using multivariable linear regression, we compared SU change among SGLT2i initiators between those with and without diabetes and then compared SU change between SGLT2i and sulfonylurea. RESULTS: We identified 28 patients with gout initiating SGLT2i (including 16 with diabetes) and 28 patients initiating sulfonylurea (all with diabetes). Among SGLT2i initiators, the mean within-group SU change was -1.8 (95 % CI, -2.4 to -1.1) mg/dL, including -1.2 (-1.8 to -0.6) mg/dL and -2.5 (-3.6 to -1.3) mg/dL among patients with and without diabetes, respectively, with an adjusted difference between those with and without diabetes of -1.4 (-2.4 to -0.5) mg/dL. The SU did not change after initiating sulfonylurea (+0.3 [-0.3 to 1.0] mg/dL). The adjusted SU change difference between SGLT2i vs. sulfonylurea initiation was -1.8 (-2.7 to -0.9) mg/dL in all patients. The SU reduction persisted regardless of urate-lowering therapy or diuretic use and the presence of diabetes, chronic kidney disease, or heart failure. CONCLUSION: Among patients with gout, SGLT2i was associated with a notable reduction in SU compared with sulfonylurea, with a larger reduction among patients without diabetes. With their proven cardiovascular-kidney-metabolic benefits, adding SGLT2i to current gout management could provide streamlined benefits for gout and its comorbidities.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Yokose C, Challener G, Jiang B, et al. Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysis. Semin Arthritis Rheum. 2024. PMID: 38657403. doi:10.1016/j.semarthrit.2024.152441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。